Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-30T19:14:47.699Z Has data issue: false hasContentIssue false

Vigo Insight Monitoring Scale in Schizophrenia (VIMS): validation in a sample of patients with schizophrenia

Published online by Cambridge University Press:  01 September 2022

R. Vazquez Noguerol Mendez*
Affiliation:
HOSPITAL NICOLAS PEÑA, Servicio De PsiquiatrÍa, VIGO, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Lack of awareness of the disease is one of the most frequent symptoms (<80%) of schizophrenia, and it is accepted to have different aspects: cognitive, related to compliance, specific symptoms, and temporary. The detection of those dimensions of insight affected, allows to select and prioritize the objectives and therapeutic strategies to improve it.

Objectives

To develop a multidimensional scale for monitoring insight in schizophrenia patients

Methods

A scale with 9 insight dimensions has been developed: appreciation of symptoms, acceptance of the cause, clinical and functional repercussions, limitations and level of competence, expected evolution and prognosis, terapeutic, and other factors. risk of decompensation. Each dimension is weighted from 0-4 points, and the result is expressed numerically and graphically. The scale was administered to 60 patients with schizophrenia on three occasions. The initial one by two psychiatrists consecutively, and the third three months after stable treatment. Other clinical and sociodemographic variables were also collected.

Results

In the analysis, reliability, internal consistency, and intra- and interobserver reliability, logical, content, criterion and construct validity were assessed, obtaining satisfactory results in Cronbach’s coefficients and Pearson’s correlation (> 0.7 and > 0.8).

Conclusions

The scale has good reproducibility, validity, sensitivity and utility characteristics, which allow its use in patients with schizophrenia.

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.